|
Compound class:
Peptide or derivative
Comment: LY3540378 is a a long-acting relaxin analogue [1]. It is composed a human relaxin mimetic peptide fused to a serum albumin-binding VHH domain. It is selective for relaxin family peptide receptor 1 (RXFP1) compared to RXFP2, 3 and 4. VHH-serum albumin binding extends the peptide's circulating half-life.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| References |
|
1. Verdino P, Lee SL, Cooper FN, Cottle SR, Grealish PF, Hu CC, Meyer CM, Lin J, Copeland V, Porter G et al.. (2023)
Development of a long-acting relaxin analogue, LY3540378, for treatment of chronic heart failure. Br J Pharmacol, 180 (15): 1965-1980. [PMID:36780899] |
